INCA-6
CAS No. 3519-82-2
INCA-6 ( Triptycene-1,4-quinone )
产品货号. M27468 CAS No. 3519-82-2
INCA-6 是活化 T 细胞核因子 (NFAT) 和钙调神经磷酸酶-NFAT 信号传导的抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥804 | 有现货 |
|
| 10MG | ¥1264 | 有现货 |
|
| 25MG | ¥2102 | 有现货 |
|
| 50MG | ¥3023 | 有现货 |
|
| 100MG | ¥4113 | 有现货 |
|
| 500MG | ¥8208 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称INCA-6
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述INCA-6 是活化 T 细胞核因子 (NFAT) 和钙调神经磷酸酶-NFAT 信号传导的抑制剂。
-
产品描述INCA-6 is an inhibitor of Nuclear factor of activated T cells (NFAT) and calcineurin-NFAT signaling.(In Vitro):In human retinal microvascular endothelial cells, INCA-6 (1.0, 2.5 μM) significantly decreases VEGF and serum-induced proliferation without affecting baseline proliferation. In 3-Hz cells, INCA-6 (5 μM) prevents transient outward K+ current downregulation. INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in rat primary microglia and BV-2 cells. INCA-6 (5 μM) protein expression and reduces SERCA2 transcript levels with and without thapsigargin.(In Vivo):INCA-6 (2.5, 5.0, and 25.0 μM; intravitreal) significantly reduces pathologic neovascularization in oxygen-induced retinopathy and decreases the severity of OIR in a dose dependent manner.
-
体外实验INCA-6 (5 μM; for 24-hour) prevents?transient outward K+?current (Ito)?downregulation in 3-Hz cells.Pre-treatment of BV-2 cells with INCA-6 (10 μM) significantly inhibits ATP-induced CXCL2 expression in BV-2 cells. INCA-6 also inhibits ATP-induced CXCL2 expression in rat primary microglia.?INCA-6 (5 μM) reduces SERCA2 transcript levels as well as protein expression, in the absence or in the presence of ?thapsigargin (TG).INCA-6 (1.0 and 2.5 μM; 24 hours?) treatment significantly decreases both VEGF and serum-induced human retinal microvascular endothelial cells (HRMEC) proliferation, but does not affect baseline proliferation. Cell Proliferation Assay Cell Line:Human retinal microvascular endothelial cells Concentration:0.5, 1.0, or 2.5 μM Incubation Time:24 hours Result:Significantly inhibited VEGF-induced proliferation at 1.0 and 2.5 μM concentrations.
-
体内实验INCA-6 (5.0, or 25.0 μM) treatment significantly reduces pathologic neovascularization in oxygen-induced retinopathy (OIR). Animal Model:Rats bearing OIR model Dosage:2.5, 5.0, or 25.0 μM Administration:Intravitreal injection on days 14(0) and 14(3)Result:Decreased the severity of OIR in a dose dependent manner. Significant inhibition was seen at 5.0 and 25.0 μM concentrations.
-
同义词Triptycene-1,4-quinone
-
通路Others
-
靶点Other Targets
-
受体prostaglandin F2α
-
研究领域——
-
适应症——
化学信息
-
CAS Number3519-82-2
-
分子量284.31
-
分子式C20H12O2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 2.86 mg/mL (10.06 mM)
-
SMILESO=C1C=CC(=O)C2=C1C3C=4C=CC=CC4C2C=5C=CC=CC53
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Baryla M, et al. Prostaglandin F(2α) stimulates adhesion, migration, invasion and proliferation of the human trophoblast cell line HTR-8/SVneo. Placenta. 2019 Feb;77:19-29.
产品手册
关联产品
-
meplazumab
meplazumab 是一种人源化抗 CD147 抗体,作为 COVID-19 肺炎患者的附加疗法。
-
HIF-1 alpha 556-574
HIF-1 alpha (556-574) is a hypoxia-inducible factor-1 19-mer fragment. HIF-1 functions as master regulator of response to oxygen homeostasis. Hypoxia-induced gene expression is initiated when HIF-1subunit is stabilized in response to a lack of oxygen. This part of HIF-1 binds to the von Hippel-Lindau factor (VHL) an E3 ubiquitin ligase, and the proline 564 is absolutely vital to the binding process.
-
P-SCN-Bn-DOTA
p-SCN-Bn-DOTA 是一种双功能螯合剂。p-SCN-Bn-DOTA 同时螯合放射性核素和连接单克隆抗体,可用于肿瘤的放射免疫研究。
021-51111890
购物车()
sales@molnova.cn

